Lineage Cell Therapeutics Reports 61% Revenue Decline in Q2 2026, Net Income Turnaround

Lineage Cell Therapeutics, Inc. reported a significant decline in financial performance for the second quarter of 2026, with total revenues of $1.07 million, a 61% decrease from $2.77 million in the same period last year. For the first half of 2026, revenues totaled $2.79 million, down 35% from $4.27 million in the prior year. The decrease was primarily driven by a $1.59 million drop in collaboration revenues, largely attributed to the company's agreement with Roche, which reflects a slowdown in progress toward completion of performance obligations. Additionally, royalty revenues fell by 46% to $126,000 compared to $233,000 in the previous year.

Operating expenses also saw a notable reduction, totaling $9.99 million for the second quarter, down 56% from $22.55 million in the same quarter of 2025. This decline was influenced by the absence of a $14.84 million impairment charge recorded in the prior year related to the VAC platform, which Lineage has since abandoned. Research and development expenses increased by 54% to $4.77 million, driven by investments in preclinical programs, while general and administrative expenses rose by 14% to $5.22 million, reflecting higher personnel costs and stock-based compensation.

Lineage's net income for the second quarter was $1.48 million, a significant turnaround from a net loss of $30.46 million in the same quarter of 2025. This improvement was largely due to a $9.44 million gain from the change in fair value of warrant liabilities, compared to a loss of $12.74 million in the prior year. The company reported a net loss of $3.33 million for the first half of 2026, a substantial improvement from a loss of $34.60 million in the same period last year.

In terms of operational developments, Lineage continues to advance its clinical programs, particularly the OpRegen therapy for geographic atrophy secondary to age-related macular degeneration, which is currently in Phase 2a trials. The company is also progressing with its OPC1 therapy for spinal cord injuries and has launched a new corneal endothelial cell therapy program, COR1, which is in preclinical development. As of June 30, 2026, Lineage had $50.8 million in cash, cash equivalents, and marketable securities, which it believes will be sufficient to fund operations for at least the next twelve months.

Looking ahead, Lineage anticipates continued investment in its research and development programs, with a focus on advancing its pipeline of cell therapies. The company is also exploring additional capital-raising opportunities, including potential collaborations and equity offerings, to support its ongoing operations and development efforts. However, it acknowledges the potential impact of macroeconomic conditions and geopolitical factors on its business and financial outlook.